Belimumab for people with early lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus within the last 2 years.
- Your lupus must be active (symptoms like joint pain, rash, or fever) and you may need to take steroids to control it.
- You must have positive blood tests for lupus antibodies (like ANA or anti-dsDNA) from at least two separate times.
- You cannot have any permanent organ damage from lupus (such as kidney scarring).
- You cannot have taken certain other lupus treatments like rituximab, cyclophosphamide, or anifrolumab in the past.
- You must be able to give yourself weekly injections at home (or have someone who can).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with systemic lupus (lupus) who have already started belimumab (a lupus medicine). It mainly focuses on whether participants who meet lupus diagnosis rules and choose to join can be followed in the study.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.